<DOC>
	<DOCNO>NCT01684748</DOCNO>
	<brief_summary>Overweight obesity , afflict ~65 % U.S. population 1 billion people worldwide , increase risk develop hypertension . Activation renin angiotensin system ( RAS ) important mechanism obesity lead hypertension . In addition vasoconstricting sodium retain action , angiotensin II also potent pro-inflammatory action include macrophage infiltration expression proinflammatory cytokine target tissue . Adipose tissue skeletal muscle appear key site generation proinflammatory cytokine . Although angiotensin II receptor blockade reduces inflammation many tissue , effect adipose tissue skeletal muscle human clear . Importantly , chronic low grade inflammatory state accompanies obesity complicate hypertension contribute insulin resistance accelerate cardiovascular disease . Therefore , general aim present proposal determine influence angiotensin II receptor blockade adipose tissue skeletal muscle inflammation relation improvement insulin sensitivity , observe , obese hypertensive human . To address aim , 44 obese ( BMI &gt; 30 kg/m2 ) hypertensive ( BP &gt; 140 systolic and/or 90 diastolic ) individual ( age=50-65 year ) randomize receive 8 week either angiotensin II receptor antagonist , olmesartan medoxomil , treatment crossover manner . Subcutaneous adipose tissue skeletal muscle biopsy obtain insulin sensitivity ( intravenous glucose tolerance test ) assess baseline follow 8 week intervention . A two week washout period separate intervention .</brief_summary>
	<brief_title>Angiotensin II Blockade Inflammation Obesity</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Prehypertension</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Angiotensin II</mesh_term>
	<mesh_term>Angiotensinogen</mesh_term>
	<criteria>1875 year age Weight stable previous 6 month ( +2.0kg ) Sedentary recreationally active Willing randomize treatment placebo Verbal write informed consent Approved participation Medical Director ( Jose Rivero , M.D . ) Blood pressure outside state range Diabetes take diabetes medication Total cholesterol &gt; 6.2 mmol/L ; triglyceride &gt; 4.5 mmol/L Past current ischemic heart disease , stroke , respiratory disease , endocrine metabolic disease , neurological disease , hematologicaloncological disease Evidence renal insufficiency ; GFR &lt; 60 ml/min* Medications ( include limit antihypertensive , statins antiinflammatory action ) antioxidant vitamins supplement Known allergy hypersensitivity olmesartan component Pregnant plan become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>angiotensin II</keyword>
	<keyword>obesity</keyword>
	<keyword>diabetes</keyword>
</DOC>